Free Newsletter
| Get the pharma industry's daily monitor, with a special focus on pharmaceutical company news and the market development of FDA approved products. Sign up for free today! |
GSK prevails in Paxil suicide suit
Pre-emption handed GlaxoSmithKline the victory in a lawsuit over a 13-year-old who committed suicide while taking the antidepressant Paxil. A California judge cited the pre-emption rule in dismissing the suit, saying that the case created a direct conflict between federal labeling requirements and state tort law. Glaxo couldn't have complied with both, the judge said, and federal law pre-empts state law--so out with the suit.
The thing is, this ruling could not only set a precedent, causing all sorts of damage suits against drug companies to get tossed, but might be a harbinger of an even bigger precedent-setter. The Supreme Court is set to consider a couple of cases that rest on this notion of pre-emption. As the reasoning goes (greatly simplified; I'm no lawyer) the federal government vested FDA with the power to regulate drugs and devices, so FDA approval should shield drugs and devices from state liability.
- check out the coverage from Pharmalot
Related Articles:
UK patients sue for Paxil withdrawal. Report
Study highlights link between Paxil and suicide. Report
Glaxo to let Mylan make generic Paxil. Report
Study: Antidepressant warnings work. Report
Comments
Post new comment
Paid Research Reports
- RNA therapy: the next big thing after monoclonal antibodies?
- Biotech M&A Strategies: Deal assessments, trends and future prospects
- The Dermatology Market Outlook to 2013: Competitive landscape, pipeline analysis and growth opportunities
- Pipeline Insight: Cancer Overview - Breast, Gynecological, Genitourinary - Diverse drugs approaching the market for many tumor t
- Sales Force Effectiveness


